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ABSTRACT

Conway, Emily D. M.S., Purdue University, August 2015. Investigations into the anticollagenase efficacy of serum and plasma. Major Professor: Jean Stiles.

Corneal ulcers are a commonly encountered problem in domesticated species and can
cause significant pain, incur a high cost for the owner, and result in blindness or eventual
enucleation. The progressive deepening of corneal ulcers is mediated by enzymatic
destruction of stromal collagen (termed keratomalacia) when collagenases from
endogenous and exogenous sources are active on the corneal surface. The inhibition of
collagenases can therefore be crucial to mitigating the damage that breakdown of corneal
stromal collagen causes. In ulcers where collagenase activity is suspected, the use of
topical serum has been recommended, in both human and veterinary medicine, primarily
due to the presence of an endogenous serum anti-collagenase protein molecule: α-2
macroglobulin. Alpha-2 macroglobulin is produced by the liver and is able to inactivate
collagenase molecules from various endogenous and exogenous sources. Plasma has also
been recommended for use, in various forms, for the treatment of various corneal
conditions. Plasma, in addition to containing α-2 macroglobulin, also contains platelets
and other growth factors that may be useful in promoting corneal healing. Despite
widespread recommendations for the topical use of serum to treat keratomalacia, there is
little data on its storage and usage in domestic species. Additionally, there is little
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information available comparing the anti-collagenase efficacy of serum to that of plasma.
The goals of this research were to determine the effects of storage time and temperature
on the anti-collagenase efficacy of serum in an in vitro corneal degradation model. This
model uses a bacterial collagenase to cause collagen degradation, which is then measured
by calculating percent corneal weight loss and quantifying the level of HP (a breakdown
product of collagen) present; serum from different time and temperature storage is added
to try to decrease weight loss and levels of HP. A reduction in percent corneal weight
loss or HP would be indicative of a protective, anti-collagenase effect of the tested
substance. An investigation into interspecies use of serum in the same model was also
undertaken, to determine if any differences in anti-collagenase efficacy are seen with
homologous serum compared to heterologous serum. In a second experiment, the anticollagenase efficacy of fresh serum was compared to that of plasma for feline, canine and
equine species. The hypothesis was that storage conditions would not affect the anticollagenase efficacy of serum and that homologous and heterologous serum would have
equal anti-collagenase efficacy. A final hypothesis was that fresh serum and plasma
would have equal anti-collagenase efficacy. For the corneal degradation model, normal
corneas from recently euthanized cats, dogs and horses were collected and stored at 80°C until use. For the first experiment serum was collected from healthy cats, dogs and
horses and pooled by species, then stored for 30, 90 or 180 days at both -20°C and -80°C.
Serum was pooled to control for any individual variation in serum composition. Sections
of cornea were dried, weighed and incubated with clostridial collagenase and serum
(homologous/heterologous) from each time/temperature point for the first experiment.
Negative control samples were incubated only in saline with added calcium chloride
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while positive controls contained saline, calcium chloride and clostridial collagenase.
Corneal damage was assessed by percent corneal weight loss and HP concentration of the
incubation fluid compared to positive and negative control samples. A Shapiro-Wilk
statistic was used to test for normality on percent corneal weight loss and HP. If the
distribution was normal, mean and standard deviation (SD) were reported, if the
distribution was not normal then median and range were reported. If the data was normal,
then a general linear model was used to compare the means across groups, otherwise the
Kruskal-Wallis test was used. If the Kruskal-Wallis test or the general linear model was
significant, then pairwise comparisons with Bonferroni adjustment. A P value of <0.05
was considered significant. Statistical software was used for all analyses. The inclusion
of serum resulted in significantly less percent corneal weight loss compared to positive
controls (P<0.001). Storage time (P=0.074) and temperature (P=0.526) did not affect
percent corneal weight loss, while interspecies cornea/serum combinations (i.e.
heterologous serum) (P=0.028) did affect percent corneal weight loss. The inclusion of
feline or equine sera significantly reduced HP concentration (P<0.001) compared to
positive controls. Significantly more HP was present in samples incubated with serum
stored for 90 days compared to all other time points (P<0.001) while temperature did not
significantly affect HP concentrations (P=0.132). For the second experiment, the ulcer
degradation model used was the same as for the first experiment. However, in the second
experiment, the sections of feline, canine and equine cornea were dried, weighed and
incubated with clostridial collagenase and fresh serum or plasma. For the second
experiment, blood was collected from healthy cats, dogs and horses; fresh serum or
plasma was pooled by species and used in the model. Serum and plasma were pooled to
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control for any individual variation in composition. To analyze the data from the second
experiment, percent corneal weight loss and HP levels were compared among groups for
positive control, serum and plasma samples with Kruskal-Wallis tests. If the KruskalWallis test was significant (i.e., P<0.05), then Dunn’s tests were performed for pairwise
comparisons. A Spearman correlation coefficient was used to assess correlation between
percent corneal weight loss and HP concentration. In the second experiment, both serum
and plasma were significantly effective at reducing percent corneal weight loss in this
model compared to positive control samples. No significant difference was found
between feline (P=0.579), canine (P=0.249) or equine (P=0.406) corneas incubated with
serum or plasma with regards to percent corneal weight loss. Canine serum and plasma
significantly reduced HP levels while inclusion of feline and equine serum or plasma did
not, compared to positive controls. Levels of HP were moderately correlated with
percent corneal weight loss for feline sample (P=0.002), weakly correlated for equine
samples (P=0.096) but were not correlated with percent corneal weight loss for canine
samples (P=0.842). These studies confirm that both serum and plasma exert an anticollagenase effect. The results of these studies suggest that serum can be stored for up to
6 months, at either -20°C or -80C°C without loss of anti-collagenase efficacy. The use of
heterologous serum may be beneficial but further research is needed before any clinical
recommendations can be made. Additionally this research indicates that plasma may be
an acceptable substitute for serum as a topical corneal anti-collagenase treatment.
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CHAPTER 1. INTRODUCTION

The cornea plays an integral role in vision, as it allows light to enter the eye, refracts
that light and provides support and protection for intraocular contents. The epithelial
surface of the cornea is composed of layers of non-keratinized squamous epithelial cells
that cover the fibrous corneal stroma, the thickest layer of the cornea. Descemet’s
membrane lines the deep aspect of the corneal stroma, as the basement membrane for a
single layer of corneal endothelial cells.1 Although corneal epithelium is maintained by a
constant cycle of growth of basal cells and sloughing of superficial cells, the corneal
stroma is more static, with only a few active cells at any given time.2

Any defect in which the corneal epithelium is missing can be termed a corneal
ulcer. Superficial corneal ulcers can heal via re-epithelialization in a matter of days. If
however, a complication such as infection or an imbalance of normal corneal
maintenance occurs, a simple corneal ulcer can extend into the stroma via enzymatic
destruction of corneal stromal collagen, often referred to as corneal melting or
keratomalacia.3 These collagenase enzymes can be released by bacteria or fungal
organisms that have colonized the ulcer, from neutrophils that invade the cornea
secondary to the insult, or can be released from corneal cells themselves. Regardless of
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the source of the enzyme, the end result is the same: degradation of stromal collagen and
deepening of the ulceration. If allowed to progress unchecked, this destruction of stromal
collagen can result in descemetoceles, corneal perforations, blindness and/or complete
loss of the globe itself (enucleation).

In an effort to slow or arrest the loss of corneal stroma due to enzyme destruction,
anti-collagenase substances have long been used, both topically and systemically, in
human and veterinary medicine.3-7 Anti-collagenases include tetracycline antibiotics,
chelating agents and blood products (serum and plasma). Blood derivatives such as
serum and plasma have some potential benefit over other topical anti-collagenases: they
are relatively easily obtained, non-toxic and generally non-irritating. The use of topical
serum is widely recommended in the veterinary and human literature as an adjunctive
measure in the treatment of melting or deep ulcers.3-7 Currently the ophthalmology
department at the Purdue University Veterinary Teaching Hospital maintains a store of
canine serum for topical use in canine and feline patients, as it can be difficult to obtain
feline serum. If a large animal patient requires serum, it is generally obtained directly or
from a healthy donor. Despite the widespread use of serum, there is a general lack of
data regarding its usage in clinical practice.

Plasma has been investigated in human medicine for its use in treating a multitude
of ocular disorders, including dry eye, chemical burns and non-healing ulcerations.
Plasma, which can be purchased commercially, has potential benefits as a topical therapy
over serum in that it is available commercially, ensuring a steady source for clinical
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usage. To the knowledge of the author, few investigations have been undertaken to
quantify the efficacy of topical canine plasma as an anti-collagenase in veterinary
medicine, and there has been no investigation of the anti-collagenase efficacy of feline
and equine plasma.8,9

The corneal degradation model used here was based off of previous work with
equine corneas, where dehydrated corneas were incubated in solution containing bacterial
collagenase and various anti-collagenases.10 The degradation model used percent corneal
weight loss and concentration of HP(a breakdown product of collagen) to quantify
collagenase induced degradation of corneal collagen.10 A reduction in corneal weight
loss and/or HP concentration would indicate efficacy of the tested anti-collagenase. The
research performed for this thesis assessed the effects of storage time and storage
temperature on the in vitro anti-collagenase efficacy of feline, canine and equine serum in
a corneal degradation model. Interspecies (heterologous) use of serum was also
investigated. A secondary portion of this research project compared the anti-collagenase
efficacy of fresh serum to that of fresh plasma in the same corneal degradation model in
feline, canine and equine species.
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CHAPTER 2. LITERATURE REVIEW

2.1

Corneal Anatomy

The globe is composed of 3 tunics: an inner neurosensory layer, a vascular layer
and an outer fibrous layer.1 The cornea, the clear anterior portion of the fibrous tunic of
the eye, plays a vital role in vision as it both provides protection of intraocular contents
and also allows the passage and refraction of light into the eye.2 The cornea is itself
protected by the upper and lower eyelids and the nictitating membrane; it receives its
nourishment from the pre-corneal tear film and from the aqueous humor that fills the
anterior chamber.1

Domesticated species have 4 distinct layers to the cornea, while humans and nonhuman primates have 5 layers.3 The layers of the cornea, from anterior to posterior are
the corneal epithelium, Bowman’s layer (human/non-human primate), corneal stroma,
Descemet’s membrane and the corneal endothelium.1-4

The corneal epithelium provides protection for the cornea and also helps to
provide a smooth outer surface for the refraction of light.5 The corneal epithelial
thickness varies among species, being slightly thicker in domestic ungulates compared to
domestic carnivores, such as the dog and cat.1 A single layer of columnar cells makes up
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the basal layer of the corneal epithelium. The basal cells are attached to the underlying
basement membrane via hemidesmosomes.2 These cells are continuously replicating and
as they do so, the cells move closer to the surface of the eye and begin to flatten out and
become polygonal in shape, at which point they are called ‘wing cells’.3 The number of
wing cells varies among species, with dogs and cats having 2-3 layers of these cells.1 As
these cells are pushed anteriorly, they become more flat and become non-keratinized
squamous epithelial cells. The basal cells, wing cells and squamous cells are attached to
one another via desmosomes which are present in greater numbers in superficial layers;
gap junctions are also found in all layers but are more numerous among the deeper
layers.2-4 Tight junctions also exist among the most superficial layers of epithelial cells,
so that a semi-permeable membrane is formed.2 These tight junctions help to prevent the
infection of the corneal stroma by organisms such as bacteria and fungi.5 These
superficial epithelial cells are subsequently shed, to be replaced by younger cells beneath
them; the entire epithelium can be replaced in 7 days.2,4,5

Briefly, Bowman’s layer is an acellular membrane located beneath the corneal
epithelium but anterior to the corneal stroma; as previously mentioned, this layer is not
present in domesticated species.1,3 When it is present, it is approximately 12 µm thick
and is located beneath the epithelial basement membrane.2 Bowman’s layer is comprised
of fibrils of collagen and proteoglycans; the function of this layer is unclear.4

The corneal stroma is the largest layer of the cornea, comprising approximately
90% of the overall corneal thickness.1-4 The majority of the dry weight of the corneal
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stroma is collagen (which accounts for 70-82% of the dry corneal weight).6,7 The corneal
stroma is composed of collagen fibrils, keratocytes and an extracellular matrix of
proteoglycans and glycoproteins.4 The collagen fibrils are uniform in both size and in
orientation; corneal collagen fibrils are arranged in parallel in numerous lamellae. Most
human collagen fibrils are 27-35 nm in diameter, although there are a few that measure
up to 70 nm in diameter.2,3,8 This uniformity allows light to pass relatively unimpeded
through the cornea. The corneal stroma contains multiple types of collagen, which are
differentiated from one another by the composition of their genetically determined
polypeptide chains.9,10 In the cornea, collagen Type I is most common and it forms
stromal fibrils; these fibrils also contain collagen type V, thought to be associated with
the uniformity and growth of the stromal collagen fibril.1,2,7,8,11-14 The majority of the
stromal fibril (80-94%) is collagen type I, the remainder is collagen type V.13,15 Collagen
type VI is only present around the collagen fibrils and is involved in the stability of the
stromal matrix and organization of the stromal fibrils.1,8,11,13,14 Collagen type III is
thought to be related to corneal development, as it is present in fetal corneas but only in
very low levels in adult corneas.1,7,11,16 Collagen type III is postulated to provide a
framework for the deposition of collagen type I during development; this may also
explain why it is present in corneal scars.16,17 Basement membranes of the cornea also
have specific types of collagen present; collagen type VII is located in corneal epithelium
and collagen type VIII is found in Descemet’s membrane.11 A human study using
immunofluorescence detected collagen type I in the corneal stroma and in corneal scars,
collagen type III in corneal scars, and collagen type IV in both the epithelial basement
membrane and Descemet’s membrane.17
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The corneal stroma also consists of an extracellular matrix made of glycoproteins
and proteoglycans such as keratin sulfate and dermatan sulfate.1-3,8 The most abundant
type of proteoglycan in the extracellular matrix is keratin sulfate.18 The extracellular
matrix is located around the fibrils of collagen and is produced in part by the various cells
of the cornea, including epithelial cells and stromal keratocytes.11,18,19 The keratocytes
present within the corneal stroma help to maintain the corneal lamellae; these cells
comprise only about 10% of the stroma.2,3 When activated after corneal wounding,
keratocytes are able to lay down new collagen fibrils and extracellular matrix, although
they cannot do so in the same uniform manner, resulting in a corneal opacity (scar).

Descemet’s membrane is a very thin, acellular membrane located just posterior to
the deep corneal stroma. This layer, which thickens slightly with age, is the basement
membrane of the corneal endothelium.2,3 Descemet’s membrane, which in the adult
human eye is approximately 15 µm thick, is resistant to degradation by enzymes.2

The final layer of the cornea, the corneal endothelium, is a single layer of
cuboidal epithelial cells that lines the inside of the cornea.4 The endothelial cells
themselves are polygonal cells, with most of the cells being hexagonal in shape, and are
connected by both gap junctions and tight junctions.2 The corneal endothelium serves an
important role in maintaining the relatively dehydrated state of the cornea, which also
contributes to corneal clarity. Sodium/potassium ATPase pumps in the endothelial cells
help to remove excess fluid from the corneal stroma, allowing it to remain transparent.1-3
The endothelial cells do not directly remove fluid from the corneal stroma; rather, they
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move ions and create an osmotic gradient which moves water from the stroma to the
anterior chamber.4 However, the number of endothelial cells decreases with age and loss
of these cells is permanent.4

Although turnover of the cornea is slow compared to other tissues, the cornea
does have a system for routine maintenance, which is accomplished by a balanced system
of removal of damaged tissue and replacement with healthy tissue.18 This maintenance of
corneal cells is managed by proteinases, which are enzymes that are able to breakdown
proteins. There are four classes of endogenous proteinases: serine proteases,
cysteine/thiol proteases, metalloproteinases and aspartic proteases.20 In the cornea, this
maintenance is mainly carried out by MMPs; a group of enzymes which affect the
proteins of the stroma and extracellular matrix.21 The MMPs are enzymes that are
released as inactive pro-enzymes, which require zinc for activation.21 MMPs can be
further characterized by the protein molecules on which they act: collagenases (which
break down collagen types I-III), stromelysins (which break down proteoglycans and
other collagens), gelatinases (which break down denatured collagens/gelatin).21-23
TIMPS are specific endogenous proteins which regulate the deposition of and breakdown
of the extracellular matrix.21,24,25 A non-specific inhibitor of MMPs, α2-macroglobulin,
is found in serum.26 A further discussion of MMPs and their role in corneal ulceration
and repair is included in the next section.
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2.2

Corneal Ulceration and Healing

Corneal ulceration is known to be a frequent cause of vision loss in humans and is
a common diagnosis in veterinary medicine. A corneal ulceration can be loosely defined
as any lesion of the cornea where the corneal epithelium is no longer present, with
resultant exposure of the corneal stroma. A simple corneal ulceration can be described as
a loss of corneal epithelium, without the presence of infection, which typically
epithelializes within 5-7 days. The healing of the corneal epithelium has 3 important
phases: cell migration, proliferation and adhesion.27 When the corneal epithelium
sustains an injury, there is a lag phase where the epithelial cells at the edge of the ulcer
will lose their attachments to the underlying basement membrane, enlarge and slide to
cover the exposed basement membrane.5,28 The movement of cells to cover the defect
begins within hours after the insult occurs and continues in a centripetal manner until the
new epithelial layer is complete.5,27 Once the defect is covered, continued division of
basal cells restores normal corneal epithelial thickness.1,5,27 As epithelial cells move to
cover the stroma, they form short term attachments to specialized ‘adhesion plaques’
which are part of the extracellular matrix and are receptors for various parts of the
basement membrane.27 Hemidesmosomes are then formed by the basal epithelial cell
layer to adhere to the basement membrane.5,27,28 As long as the epithelial basement
membrane is intact, the epithelial cells can adhere to it strongly in a matter of days, with
the epithelium becoming functionally normal.8 If a very large area of corneal epithelium
is lost, new basal cells are supplied by stem cells at the corneal limbus, where the cornea
and sclera meet; larger epithelial defects take longer to heal.1,5,8,29 In cases where the
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basement membrane has been damaged, it can take longer for the epithelium to develop a
firm attachment, as epithelial cells must secrete new basement membrane.8,27,28

A complicated ulcer then can be described as an ulceration that has extended into
the corneal stroma, often due to infection, which would not be expected to heal within 57 days. As soon as a few hours after stromal injury, PMNLs will arrive at the site of
injury from the pre-corneal tear film, followed by activation of stromal keratocytes.5,28,29
Keratocytes play an important role in corneal wound healing, as they will either undergo
cell death or become activated into cells that can repair the damaged stroma.30 A short
time after the corneal epithelium is lost, the keratocytes directly beneath the area become
apoptotic; this is thought to be due to the release of interleukin-1 from the remaining
epithelial cells.30 If the basement membrane of the epithelium is damaged, some of the
keratocytes become activated, assuming many characteristics of fibroblasts, and move
towards the damaged, acellular area.30,31

Within days of injury, the activated keratocytes begin to secrete collagen,
proteoglycans and glycosaminoglycans; this new collagen is larger in diameter and is laid
down in a disorganized manner.24,29 Keratocytes are also able to transform into a
myofibroblast type of cell, which assist with the contraction of the wound in addition to
contributing to the extracellular matrix.30 Fini used a rabbit penetrating keratectomy
model to investigate corneal repair.18 A fibrin plug was allowed to fill the defect, this
plug was epithelialized within 48 hours. At 24 hours, activated keratocytes had moved
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into the fibrin plug and by 2 weeks post injury, the defect was primarily repaired
stroma.18

As the cornea heals, the ratio of collagen proteins changes. In one study, the
ratio of collagen type I to collagen type V decreased, as type V collagen increased during
the healing phase.31 In human cadaver corneas from keratoconus patients treated with a
corneal graft, collagen type III was detected by immunofluorescence in the healed cornea
and in the corneal scars.17 Wound strength increases as the amount of new collagen
deposited increases, and continues to stabilize over a period of weeks to months.28,29

Several research projects have investigated the ability of the rabbit cornea to heal
after wounding.32,33 In a penetrating keratectomy model, Cintron found that the amount
of DNA present increased during healing compared to normal tissue, then decreased over
time until it reached normal levels, 10-13 weeks after the initial wound.32 Over a similar
time period, the amount of collagen present also increased, reaching more normal levels
by approximately 9 weeks post injury. Extracellular matrix proteins not normally found
in adult cornea were also detected. Taken together, these findings were interpreted as
regeneration of the corneal stroma. Interestingly, despite collagen levels becoming more
like normal cornea over a period of weeks to months; corneal transparency only returned
to a near-normal state 1.5 years after the keratectomy.32

In 1978, Cintron examined the structural changes to rabbit corneas after
penetrating keratectomy, finding that identifiable corneal lamellae were not present in the
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scar tissue 3 weeks after the surgery; rather the fibrils were irregular in both orientation
and size.33 Even at over a year post injury, the fibrils present in the corneal scar were
arranged differently to that of normal stroma.33

As previously mentioned, proteinases are important for corneal maintenance,
wound healing and include MMP-1 (collagenase 1), MMP-2 (65 kD gelatinase/gelatinase
A), MMP-3 (stromelysin 1), MMP-7 (72 kD gelatinase), MMP-9 (92 kD
gelatinase/gelatinase B) and MMP-13 (collagenase 3). Stomelysins (including MMP-3)
are able to break down proteoglycans, while collagenases (including MMP-1) break
down collagen types I, II and III. 23,34 Gelatinases (MMP-2, MMP-9) degrade collagen
types IV, V and VII and can also break down denatured collagen.23,34 TIMP-1 and
TIMP-2 are both also involved in corneal wound healing.21 Both MMP-2 and MMP-9
are important with regard to stromal collagen. Both MMP-2 and MMP-9 can be
produced from corneal epithelial and stromal cells and research has shown their levels
increase after surgical keratectomy.35 It has been suggested that MMP-2 is active both in
maintenance of the normal cornea and in remodeling of the stroma after corneal injury.3537

In contrast, MMP-9 is not secreted unless corneal damage occurs; after corneal injury

epithelial cells, keratocytes and polymorphonucleocytes can produce it.12,22,35,36 It has
been suggested that MMP-9 may assist in remodeling the epithelial basement membrane
and enabling re-epithelialization.12,22,35,36 In an experimental study, MMP-9 was present
early after corneal wounding but was no longer detectable within 4 weeks of the original
insult.12 Derangements in the regulation of MMPs have been implicated in many disease
processes, including neoplastic and cardiovascular disorders .38
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Analysis of levels of MMP’s in tears has been investigated with regard to corneal
ulcerations in veterinary species. The activity of MMP-2 and MMP-9 were evaluated in
the tears of 10 horses with ulcerative keratitis over the course of their disease.39 Total
tear MMP activity was significantly higher in ulcerated eyes compared to the normal eye
and the mean activity of the MMPs decreased between hospital admissions and healing of
the ulcer.39 In dogs, tear samples were collected from canine patients with Pseudomonas
aeruginosa associated keratitis and concentrations of MMP-2 and MMP-9 were
assessed.40 The levels of both latent and active MMP-2 and MMP-9 were higher in
affected eyes compared to non-affected contralateral eyes; levels of both were also
significantly less once affected eyes healed compared to when they were first evaluated.40

In human medicine, the pre-corneal tear film has also been evaluated with regards
to healthy and ulcerated corneas. Prause examined the concentrations of PMNL neutral
collagenolytic protease in the tears of 53 healthy persons and from 18 eyes of 16 people
with melting corneal ulcers.41,42 The protease was not found in the tears of any of the
healthy patients but was found in the tears of those patients with melting corneal ulcers.
Prause was also able to show a decrease in the amount of the protease in the tear film as
the corneal ulcers healed.42

Finally, cytokines are also important for the healing of corneal ulcerations. EGF,
FGF, TGF-β, PDGF, substance P and others, arising from the pre-corneal tear film,
corneal nerves and epithelial and stromal cells, have been found to have beneficial effects
on corneal healing.28
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2.3

Collagenases

Corneal ulcers can occur for a myriad of reasons, including trauma, infection,
chemical or thermal burns, nutritional deficiency, autoimmune diseases and others.23,43,44
Despite the many possible causes of ulceration, one fact remains constant: the destruction
of collagen allows for ulceration to progress. Ulcers that have extended into the corneal
stroma are mediated by uncontrolled enzymatic breakdown of stromal collagen. This
unregulated breakdown of corneal collagen is clinically termed keratomalacia or corneal
melting. Collagenases are enzymes that have the ability to break down collagen; in vivo,
collagenases have been found in eyes which have sustained chemical or thermal burns.8
Although collagenases can also be produced by infectious agents, endogenous
collagenases from white blood cells, corneal epithelial cells or stromal
keratocytes/fibroblasts themselves have been implicated in the progression of stromal
loss.12,28,35-37,45 MMP-1 and MMP-2 and MMP-9 can be produced by corneal epithelial
cells and keratocytes after corneal injury, although most MMP-9 is produced by epithelial
cells.46 In 1969, investigation of bovine cornea revealed peptidase activity and a
collagenase capable of breaking down stromal collagen was identified from rabbit
corneal epithelium.47,48 Corneal collagenase isolated from rabbits has been found to be
functional at physiologic pH and it has been documented to cleave collagen fibrils into ¾
and ¼ lengths, which is a characteristic of mammalian collagenases.49,50 Human corneal
collagenase has been found to be a true collagenase.51

Other sources of collagenase, including PMNLs, bacteria and fungi have been
investigated as well. An in vivo study was undertaken to determine if rabbit corneal
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collagen could be broken down by intra-stromal injections of active (lysed) PMNLs.52
Injection of lysed PMNLs resulted in active corneal collagenolysis while the injection of
heat inactivated PMNLs did not cause collagenolysis.52 A later study also investigated
the effects of PMNL in stromal ulceration, where alkali burned rabbit corneas were
treated with glued on contact lenses in an attempt to prevent stromal ulceration.53 In this
study, the presence of a glued on methyl methacrylate lens prevented both infiltration of
PMNL and epithelialization of the ulcer; it also prevented ulceration of the stroma itself.
In rabbits where the lens was removed and epithelialization of the ulcer was allowed to
take place, infiltration by PMNL and stromal ulceration followed. Thus Kenyon et al.
postulated that growth of the corneal epithelium could encourage the infiltration of
stromal PMNL, which resulted in further breakdown of corneal stroma.53 In rabbit
corneas that were already infiltrated with PMNL, prevention of epithelialization by either
mechanical debridement or placement of a methyl methacrylate ring was not enough to
prevent progressive ulceration of the corneal stroma. This demonstrated that PMNL were
able to cause corneal melting on their own.53

Bacterial infection of the cornea can contribute to corneal collagen breakdown,
through the release of proteolytic enzymes and also by stimulating an immune response
where PMNL influx can result in collagenolysis.54 The bacterium Pseudomonas
aeruginosa is known to be particularly destructive with regards to corneal melting.
Brown identified an enzyme from 5 different strains of Pseudomonas aeruginosa that
was able to degrade the proteoglycan matrix of rabbit corneas after intra-stromal
injection, despite the fact that this enzyme was not able to degrade the collagen fibrils
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present.55 These findings were corroborated by a later investigation where rabbit corneas
were experimentally infected with Pseudomonas aeruginosa.56 Histological sections of
affected corneas showed loss of proteoglycans but normal collagen fibrils. This was in
contrast to rabbit corneas treated with a collagenase from Clostridium histolyticum, where
histologic examination showed damaged corneal collagen fibrils.56 Another investigation
into the effect of Pseudomonas aeruginosa on rabbit corneas determined that a
combination of the protease produced by the bacterium and endogenous collagenases
released by the host were responsible for corneal melting.57

Fungal organisms have also been identified as sources of enzymes capable of
degrading stromal collagen. A clinical strain of Aspergillus flavus was isolated from a
human case of severe fungal keratitis; the organism was able to produce 3 different types
of proteases (metalloproteinase, serine and cysteine), all of which were able to degrade
collagen in vitro.58

Regardless of the source of these destructive enzymes, they contribute to the
breakdown of the corneal stroma. Continued loss of the stroma can result in devastating
consequences for the patient, including loss of vision and/or the globe itself. As such,
blockage of collagenase enzymes can be significant in mitigating further damage to the
globe
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2.4

Corneal Anti-Collagenases

Many agents have been recommended, in conjunction with other therapies (such
as antibiotics and antifungal agents), to slow or stop the enzymatic destruction of stromal
collagen in order to reduce the potential complications of corneal ulcers.44,59-62 Anticollagenase agents that have been investigated in relation to corneal disease include
tetracycline antibiotics, NAC, EDTA, cysteine, ilomostat, tetanus antitoxin and others.

As has been previously noted, many collagenases are secreted as inactive and they
require calcium and/or zinc to become functional.21,49 As such, use of chelators such as
EDTA and NAC have been recommended.8,45,59 Both sodium and calcium EDTA are
able to inhibit collagenase in vitro and have been recommended for use in veterinary
patients as topical anti-collagenases.44,49,62 Another chelator, NAC, has also been
investigated and recommended for use.44,62 The inhibitory effect of sodium and calcium
EDTA and NAC were investigated and found to be maximally inhibitory in vitro at
concentration of 102 molar.49 The effect of NAC use was examined on rabbit eyes in vivo
and was found to be irritating at concentrations of 20%.63 Berman refutes this from
personal experience, where rabbits treated with topical NAC did not show any adverse
effects.59 Since both EDTA and NAC are not able to irreversibly bind calcium (although
NAC is less susceptible to reversibility), their anti-collagenase efficacy is
reversible.49,55,62 This means that they must be used frequently in order to continue to be
effective, although it was postulated NAC would be the better anti-collagenase based on
their finding that it’s anti-collagenase effect was better conserved in vitro compared to
EDTA.49
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Tetracycline antibiotic have been recommended for use both systemically and
topically in many ophthalmic disorders: dry eye, blepharitis and corneal ulceration.64
Their use has been recommended as they possess anti-collagenase activity that is
unrelated to their antibiotic activity.64-66 An in vitro experiment tested minocycline,
doxycycline and tetracycline on collagenase from rats’ PMNL and found that all 3
substances could inhibit the collagenase by approximately 90%, compared to 0%
inhibition by ampicillin and cefazolin.66 The use of tetracycline antibiotics has been
recommended clinically in the treatment of melting corneal ulcers.44,60

Multiple anti-collagenase agents were investigated with regards to their ability to
inhibit MMP-2 and MMP-9 from the tear film of horses suffering from ulcerative
keratitis.67 Doxycycline, EDTA, NAC, Ilomostat, α1-PI and fresh equine serum were
tested in vitro on tear samples obtained from ulcerated equine eyes. The total MMP
activity was reduced by 96.3 % (doxycycline), 99.4% (EDTA), 98.8 %( NAC), 98.9%
(ilomostat), 90% (equine serum), 52.4 (0.1% α1-PI) and 93.6% (0.5% a1-PI) when
compared to the MMP activity of untreated equine tears.67

Synthetic collagenase inhibitors have also been investigated for anti-collagenase
efficacy. Galardin (ilomostat) is a modified dipeptide which was investigated against a
Pseudomonas aeruginosa protease in vitro and in vivo. Galardin was effective in vitro
and was able to slow the onset of corneal melting in vivo in rabbits, although it was
ultimately unable to prevent corneal melting.68 A synthetic thiol based peptide was tested
on rabbit corneas which had been experimentally infected with Pseudomonas
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aeruginosa.43 Compared to affected eyes treated with gentamicin or the negative control
vehicle, treatment with the peptide was able to significantly delay corneal melting.43

Other therapies have been utilized to prevent corneal melting, with varying
degrees of success. A study by Haffner et al. compared the anti-collagenase efficacy of
tetanus antitoxin against that of equine serum and NAC in an in vitro model.69 It was
found that all 3 substances were able to decrease corneal collagen breakdown by 50%
compared to positive control samples.69 Corneal cross linking, a procedure where
riboflavin is applied to the cornea and exposed to ultraviolet light leading to the
development of new bonds among the corneal stoma, has been reported to be effective at
arresting corneal melting in horses, dogs and cats.70-71 This therapy however, requires
specialized equipment to perform and is not widely available. Aloe vera was recently
tested in vitro as an anti-collagenase. In this particular experiment, aloe solution was not
able to block collagenase mediated destruction of collagen type I or gelatin; furthermore
it actually increased the degradation of collagen type IV by the same enzyme.72 One final
recommended anti-collagenase is serum, which will be discussed in depth in the next
section.

2.5

Serum

The Book of Dede Korkut, a book of Turkish stories from five centuries ago, tells
of a blind woman who regains her sight after rubbing her eyes with blood; it has been
postulated that this text describes the first ever use of serum as an ocular treatment.73 The
topical use of serum was recommended initially due to anecdotal evidence that corneas
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that were vascularized did not ulcerate and the discovery that human serum contains
collagenase inhibitors.59,74 In a set of experiments investigating the anti-collagenase
efficacy of serum, it was discovered that α1-antitrypsin was capable of inhibiting rabbit
corneal collagenase although it did not inhibit human corneal collagenase; this protein
was also not inhibitory against human collagenase in another investigation.74,75 Alpha-2
macroglobulin was found to inhibit both human and rabbit collagenase.74 A later study
determined that the α-2 macroglobulin found in human and rabbit serum was able to exert
its anti-collagenase action by forming complexes with the corneal collagenase.76

The serum protein α2-macroglobulin is produced by the liver; in humans it
comprises 8-10% of serum proteins.77 It is a 725 kilo Dalton glycoprotein comprised of 4
large sub-units.26,78 The primary function of α-2 macroglobulin is to control any
excessive activity of proteinases that are present in the body; α-2 macroglobulin is a
significant inhibitor of collagenase; more than 90% of the anti-collagenase efficacy of
serum is due to α-2 macroglobulin.26,75,78,79 It is important to note that α-2 macroglobulin
is a non-specific proteinase inhibitor, which means it is able to bind enzymes from all 4
classes of proteinases: serine, cysteine, aspartic and metalloproteinases.78 Each α-2
macroglobulin is able to tightly bind collagenase molecules, rendering them inactive.80,81
However, Berman notes that the large size of α-2 macroglobulin means that it is unlikely
to become extravasated, which limits its natural utility, even when ulcerating corneas
become vascularized.45 This potential setback could be overcome by using serum
topically, directly applying α-2 macroglobulin to the corneal ulcer.
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Topical usage of autologous serum is widely recommended in the human and
veterinary literature to treat a variety of ocular conditions.44,59-62,82-84 In the human
literature, serum has been recommended to treat dry eye, persistent epithelial defects and
recurrent corneal erosions, neurotrophic keratopathy, superior limbic keratoconjunctivitis,
aniridic keratopathy and Mooren’s ulcers.84 Despite this, in the human literature,
although there are various recommendations for the production, use and storage of serum
for topical usage, there is little clinical data regarding such claims. One report details the
production and storage of serum for human ocular use at two different locations.82 At the
University of Lubeck in Germany, autologous serum is to be stored at 4°C for no greater
than 16 hours or can be stored for up to 3 months if frozen at -20°C.82 The National
Blood Service in Wales and England stores blood at 4°C for 2 days; once obtained, the
serum is frozen at less than -30°C and can be stored for up to 6 months, but should be
discarded after 1 day of use.82 No data are given to support these recommendations. In
2005, a report was published detailing an optimized protocol for the production of
autologous serum eye drops.83 This study examined the effects of preparation method on
several factors contained in serum (fibronectin, growth factors and vitamins) and tested
their ability to stimulate cell growth in a cell culture model.83 They recommend allowing
the blood to clot for longer than 120 minutes, centrifuging at 3000 g for 15 minutes
followed by dilution of the serum with balanced salt solution. They then recommend
storing the serum at – 20°C for up to 3 months; once in use bottles are stored at 4°C and
discarded after 16 hours.83 No data is given in support of the storage recommendations,
only with regards to the collection of the serum. Tsubota et al. analyzed the effects of
storage time on the concentration of EGF, TGF-β and vitamin A in human serum, which
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was stored for one month at 4°C and 3 months at -20°C.85 The results of this study
showed that the concentrations of the measured components did not change significantly
over the storage time periods; no investigation into the storage effect of α-2
macroglobulin was undertaken.85

In veterinary medicine, there also exist many recommendations for the use of
topical serum in melting ulcers. Again however, there is little published data to support
the claims made for the use and storage of serum for ocular use. One report notes that
serum can be stored indefinitely if frozen, but it does not provide a specific temperature.62
A single abstract investigated the effects of storage time and temperature on the anticollagenase efficacy of serum using an in vitro model. In this model, equine serum was
stored for 7 days at – 18C°C, 4°C and 23°C and the ability of the serum to inhibit MMPs
from equine tears was measured daily.a There was no difference in inhibitory activity of
the serum from the various storage temperatures and no decrease in efficacy was noted
over the 7-day period.a

There are potential drawbacks to topical serum usage in veterinary medicine. It is
possible to use autologous serum, although the volume that can be obtained varies based
on patient size. Additionally manual or chemical restraint may be needed to draw blood
for serum; this may not be safe for the patient in question. Healthy donor animals may be
available although concern for the transmission of pathogens exists, particularly viral
agents with feline donors. Additionally, since no preservative is included with serum, the
possibility of bacterial contamination exists.84 Finally a human patient using topical
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autologous serum developed a peripheral corneal infiltrate in the superficial corneal
stroma that was later determined to be immunoglobulin deposition (IgA, IgG, IgM);
serum was suspected to be the source of the immunoglobulins.86
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2.6

Plasma

Plasma is another component of blood that has received considerable attention in
the human literature for use in various ocular conditions. Plasma is the supernatant of
blood obtained after anticoagulated blood has been centrifuged, leaving red and white
blood cells behind. Plasma contains clotting factors and platelets, which is what
differentiates it from serum. Platelets contain many growth factors including EGF,
PDGF and TGF-β which are released from activated platelets; plasma also contains fibrin
and fibronectin, which are important factors for cell adhesion and migration.87 There are
various iterations of plasma available, including PRP, FFP and platelet releasate (a
product where platelets are activated to release their contents after which the platelet
remnants are removed). The fraction of plasma with greater numbers of platelets
compared to normal plasma, where the increased concentration of platelets is achieved
through centrifugation steps, is PRP.87 Another form of plasma, E-PRP has been
described for use both as a topical drop and as a ‘clot’ for ocular use. E-PRP is plasma
located nearest the red blood cells in a centrifuged tube and has a platelet concentration
of 1-3 times that of blood.87,88 The concentration of platelets in blood ranges from
150,000 to 450,000 per microliter; in contrast PRP drops have a platelet count of
800,000/µL and PRP clots have platelet counts of 4,000,000/µL.89 PRP clots are formed
when PRP is mixed with thrombin and calcium, which causes a gel to form.89 RFRP is
plasma with higher fraction of growth factors; after centrifugation, plasma can be divided
into 2 or 3 fractions. The first is closest to the red blood cells and has more growth
factors and platelets, the second is just above the first and is higher in migratory factors
(fibronectin, vitamin A) and the third fraction is uppermost, with all the factors but at
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lower concentrations.90 Platelet releasate is a plasma product where platelets are
activated in vitro with thrombin to release their growth factors, centrifugation then
removes any platelets, leaving behind a growth factor rich supernatant.91

In the human literature, plasma has been applied as an eye drop, as a
subconjunctival injection and in clot form to treat a wide variety of corneal conditions,
including chemical burns, corneal perforations, dry eye, and non-healing ulcers.88-90,92-94
The majority of the research in the human field has focused on the role of regenerative
factors in plasma, rather than its anti-collagenase effects. Topical PRP promoted faster
epithelialization in cases of corneal chemical injury compared to standard treatment with
topical antibiotics, topical steroids and other topical medications; subconjunctival RFRP
(in addition to conventional treatment with topical medications including topical steroids
and antibiotics) reduced the time to corneal and conjunctival epithelialization in patients
with ocular alkali burns compared to those treated with conventional treatment
alone .90,92,93 In a study where patients with dry eye were treated with autologous PRP
drops, patients reported a significant improvement in symptoms.94 In another clinical
study, autologous PRP drops or clots were used to treat patients with non-healing corneal
ulcers, using a decrease in the size/depth of the ulcer as an outcome measure and 38/40
eyes were noted to improve over 3-45 days.89 E-PRP has been investigated as a way to
treat corneal perforations. E-PRP was mixed with calcium chloride to activate the
platelets and form a solid clot; the clot was then placed in the perforation and covered
with an autologous fibrin membrane in 11 patients. In all 11 cases, the perforation was
sealed, with no recurrence of perforation over a 3 month follow-up period.88
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Several studies have compared serum to plasma, with regards to the
epitheliotrophic capacity of each product. Epithelial cell proliferation is enhanced by
FGF, HGF and PDGF.91 The migration and proliferation of epithelial cells is enhanced
by EGF.91 Migration of corneal epithelial cells is also enhanced by fibronectin; vitamins
A and E affect cell differentiation and survival, respectively.91 Hartwig et al. compared
serum to platelet releasate in an in vitro corneal epithelial model.91 They found that
serum had higher levels of vitamins A and E, fibronectin and HGF, while platelet
releasate had higher levels of EGF, FGF, TGF-β and PDGF.91 In the same study, they
note that serum supported epithelial cell differentiation and migration slightly better
while platelet releasate significantly supported cell growth.91 In 2005, Hartwig et al.
compared FFP to serum in an in vitro corneal cell model, this time comparing the levels
of PDGF, EGF, TGB-β, and Vitamin A.95 In these results, serum had higher levels of
EGF, TGF- β, PDGF and vitamin A; in contrast to their previous report, serum was
superior to FFP at encouraging cell differentiation, growth and migration.95 In 2006
another study comparing epitheliotrophic factors was published in which serum, FFP and
platelet releasate were evaluated.96 In this study, the levels of TGF-β, EGF, PDGF,
vitamins A and E, and fibronectin were measured and compared in a corneal epithelial
cell culture model.96 Their results showed that proliferation of epithelial cells was better
with platelet releasate (which had higher levels of EGF, PDGF and TGF- β) but cell
differentiation and migration were supported by serum ( which had higher levels of
vitamins A and E and fibronectin).96 They concluded that FFP was not likely to be of
benefit in treating corneal disease. Again, this research was not focused on the anticollagenase efficacy of any of the plasma products and no quantification of α-2
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macroglobulin was measured.96 Interestingly a single report has noted that the
concentration of α-2 macroglobulin in human API-PRP was increased 5-10 fold
compared to the α-2 macroglobulin concentration of blood.b

In veterinary medicine, there is significantly less information regarding the use of
topical plasma. In general, plasma may hold some benefits over the use of serum as an
anti-collagenase, primarily that it is available commercially and this could provide a
steady supply for clinical use. Additionally, commercially available plasma is obtained
from animals that have been tested for communicable diseases. A recently published
abstract detailed a comparison of canine serum, plasma and FFP and their effects in vitro
in a commercial gelatinase-collagenase assay.97 The results of this study showed that all
3 blood derivatives significantly blocked collagenase and gelatinase activity in the in
vitro model but that serum was more effective than plasma.97 Another study compared
the anti-gelatinase efficacy of canine serum, FFP, freeze-thaw cycled plasma and
Solcoseryl using a commercially available gelatinase activity assay.98 Solcoseryl is an
ultrafiltrate of calf blood which is protein free and has been proposed to improve wound
healing.98 In this study, the plasma and serum showed similar blockage of MMP 2 and 9,
while Solcoseryl significantly blocked MMP-9 but not MMP-2.98 To the authors
knowledge, no investigations into the anti-collagenase efficacy of feline or equine plasma
have been performed.
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2.7

Conclusions

The volume of evidence for use of topical serum as an anti-collagenase is
convincing despite the fact that there is not a great deal of information regarding how
serum for topical use should be stored. In addition, little research has been performed
assessing the effects that storage may have on serum’s anti-collagenase efficacy. To the
authors knowledge, no previous research has evaluated interspecies use of serum. This
research serves to provide more concrete data to guide clinicians on how to store serum
for clinical use, as well as providing the first investigation into interspecies use of serum.
Finally, this research compares the in vitro anti-collagenase efficacy of serum to plasma
in cats, dogs and horses, which has potential implications for providing a stable supply of
an effective topical anti-collagenase agent to veterinary patients.
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3.2

Abstract

Objective−To evaluate interspecies effects, storage time, and temperature on the
anti-collagenase efficacy of canine, feline and equine serum in an in vitro corneal
degradation model. Samples−Normal corneas from recently euthanized dogs, cats and
horses; serum from healthy dogs, cats, and horses. Procedures− Serum was pooled by
species and used fresh or stored for 30, 90, or 180 days at both -20°C and -80°C.
Corneas were collected and stored at -80°C. Sections of cornea were dried, weighed and
incubated in saline with clostridial collagenase and serum (homologous or heterologous)
from each time/temperature point. Corneal damage was assessed by percent corneal
weight loss and hydroxyproline (HP) concentration compared to controls.
Results−Addition of serum resulted in significantly less percent corneal weight loss
compared to positive controls (P<0.001). Storage time (P=0.074) and temperature
(P=0.526) did not affect percent corneal weight loss, while interspecies cornea/serum
combinations (P=0.028) did affect percent corneal weight loss. The inclusion of feline
and equine sera significantly reduced HP concentration (P<0.001) compared to positive
controls. Significantly more HP was present in samples incubated with serum stored for
90 days compared to all other time points (P<0.001) while temperature did not
significantly affect HP concentrations (P=0.132). Conclusions and Clinical
Relevance−Serum was effective at reducing percent corneal weight loss in this model
across species. Storage time and temperature did not affect the anti-collagenase efficacy
1to 6 months at -20°C or -80°C without loss of efficacy.

40
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Introduction

Corneal ulceration is a common clinical problem in domestic species. Corneal
ulcers affecting only the epithelium often heal with minimal clinical intervention while
ulcers involving the corneal stroma may be more difficult to treat.1-3 Significant
complications can result from stromal collagen destruction which can cause rapid
progression of the ulcer to a descemetocele or a corneal perforation.2-5

Enzymes capable of degrading protein have been implicated in the progression of
human, rabbit, equine and canine corneal ulcers.1,2, 5-9 The nomenclature for such
enzymes varies among sources and the distinctions between names of proteolytic
enzymes have historically been confusing.10, 11 Terms commonly used in the literature
include collagenases, MMPs, proteinases, proteases, peptidases, gelatinases and
stromeolysins. Often, the terms are used interchangeably but for the purposes of this
study, the term collagenase is used to describe an enzyme capable of corneal collagen
degradation. Rabbit corneal collagenase, described as a tissue collagenase as it cleaves
collagen into ¾ and ¼ fragments, has been implicated in the ulceration of rabbit corneas;
human corneal collagenase was shown to breakdown collagen in the same manner.7
Collagenases can be produced by bacteria, leukocytes or from the growth of corneal
epithelium and keratocytes.1-4, 7-9,12 Regardless of the inciting cause, the progression of
stromal ulcers is mediated by collagenases as they breakdown stromal collagen.1-4,6-8,13,14
In both dogs and horses, levels of MMPs were higher in ulcerated eyes than in the
contralateral unaffected eyes and the levels decreased significantly as the ulcerations
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healed.5, 9 As such, inhibition of collagenase can be key to halting the progression of
corneal ulceration, minimizing sequelae and promoting corneal healing.1-3, 6, 8,12, 13

Many topical ophthalmic agents have been utilized clinically as inhibitors of
corneal collagenase, including calcium-EDTA, NAC and tetracycline.1-4, 6, 14 The use of
topical human serum as an effective inhibitor of corneal collagenase has been described.6,
7, 13

The inhibitory effect of serum was found to be due to α-2 macroglobulin which forms

tight complexes with collagenases and inhibits their activity.6,7,15,16

In veterinary medicine, autogenous or homologous serum has been used topically
for its anti-collagenase properties to treat corneal ulcers involving the stroma.1-4, 8 Despite
the widespread usage of topical serum as an anti-collagenase agent, to the authors’
knowledge, there is no information regarding the anti-collagenase efficacy of serum after
storage longer than 7 days in human or veterinary medicine, and no comparison of the
differences between the use of heterologous and homologous serum.

We hypothesized that serum stored up to 6 months at -20°C or -80°C would have
the same anti-collagenase efficacy as fresh serum when evaluated in an in vitro corneal
degradation model. Additionally we hypothesized that the anti-collagenase efficacy of
heterologous serum would not differ from that of homologous serum.
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3.4

Materials and Methods

Corneal Samples−Corneas were collected from recently euthanized dogs, cats and
horses from Purdue University Veterinary Teaching Hospital or a local animal shelter.
Animals were euthanized for reasons unrelated to this study and had no evidence of
corneal disease as determined by examination with a direct light source. The corneas
were removed and sectioned into 4 pieces (feline and canine) or 6 pieces (equine) of
roughly equal size within 2 hours of euthanasia. Each piece of cornea was stored
individually, labeled by species and kept at -80°C until use. Due to the extended nature of
the study, corneal sections were stored for varying lengths of time, up to 6 months.

Serum Samples−Serum was obtained from healthy canine (n=4), feline (n=6) and
equine (n=4) donors. Cats were anesthetized for blood collection, whereas dogs and
horses were manually restrained. Blood was collected into serum separator tubes, allowed
to clot and centrifuged to separate the serum. The serum was then removed and pooled by
species. The pooled serum was then divided into aliquots and used fresh, or stored for 30,
90 or 180 days, at both -20°C and -80°C. All procedures were approved by the Purdue
University Animal Care and Use Committee. Sterile technique was used throughout the
experiment but at no time were any cultures performed on serum samples.

In Vitro Corneal Degradation Model−A previous report by Haffner et al.12 provided
the basis for the current experimental design, utilizing a clostridial collagenase to incite
corneal degradation. Individual corneal samples were placed in plastic weigh boats and
dried in a 40° C oven for 3 hours. After drying, the pre-treatment corneal weight was
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recorded. Incubation fluid was prepared by adding 800 U/mL of collagenase derived
from Clostridium histolyticuma to 5 mM calcium chloride in 0.9% sodium chloride. Five
mL of the resultant solution was added to a 10 mL tube. Then 500 µL of serum (100
µL/mL) from the appropriate species and storage time/temperature combination was
added to each tube. Negative controls consisted of 5 mL of 5 mM calcium chloride in
0.9% sodium chloride only. Positive controls consisted of 5 mM calcium chloride in
0.9% sodium chloride with 800 U/mL of clostridial collagenase but no serum. Negative
and positive controls were included for each experimental condition. The dried corneal
samples were added to the tubes and incubated with agitation at 40°C for 4 hours. After
incubation, 1.8 mL of incubation fluid was collected from each tube and stored at -80°C
for HP analysis at a later date. The cornea was then collected by pouring the remaining
solution through Whatman filter paperb. The corneas were then dried at 40°C for 3 hours,
weighed and the post treatment percent corneal weight loss recorded.

Corneal samples from each species were incubated in homologous serum and two
heterologous sera. Each experiment was carried out in triplicate. Experimental
conditions are summarized below.

Homologous serum−Corneas from each species were incubated with pooled
homologous serum stored at -20°C and -80°C for time periods of 0 (fresh serum), 30, 90
or 180 days.
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Heterologous serum−Corneas from each species were incubated in heterologous
serum stored at -20°C and -80°C for time periods of 0 (fresh serum), 30, 90 or 180 days.

HP Assay− As HP is a known breakdown product of collagen and has been used
previously in a similar study, HP concentrations were used as a second means of analysis
of corneal degradation.12 A commercial HP spectrophotometric assay kitc was used to
measure HP concentration in µg/mL in the incubation media for all samples and controls.
The analyses were performed according to kit instructions with two modifications.
Modifications included that samples were diluted 1:2 with ultrapure water prior to
analysis to ensure HP concentrations measured would fit on the standard curve and
samples were centrifuged for 10 minutes at 10,000 rpm. A new standard curve calculated
for each plate.

Statistical Analysis−A Shapiro-Wilk statistic was used to test for normality on percent
corneal weight loss and HP. Mean and standard deviation (SD) were reported if the
distribution was approximately normal, otherwise median and range were reported. A
general linear model was used to compare the means across groups if the distribution was
approximately normal, otherwise the Kruskal-Wallis test was used. Pairwise comparisons
with Bonferroni adjustment were performed if the overall F test of the general linear
model or Kruskal-Wallis test was significant. A P value of <0.05 was considered
significant. Statistical software was used for all analyses.d
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Results

In Vitro Corneal Degradation Model−This model was effective at producing corneal
weight loss by collagen degradation. The percent corneal weight loss for feline, canine
and equine corneas incubated in feline, canine and equine sera, including positive and
negative controls are shown in Table 3.1.

Serum was effective at reducing percent corneal weight loss compared to positive
controls in this study. Across species, inclusion of feline, canine and equine serum
lessened corneal weight loss by 38 percent (P<0.001), 11 percent (P<0.001) and 25
percent (P<0.001) respectively compared to mean positive control samples. Overall,
corneas incubated in feline serum had the least percent corneal weight loss compared to
canine or equine serum (P<0.001). Furthermore, the percent corneal weight loss differed
significantly among different cornea/serum species combinations (P=0.028) Significant
differences are summarized in Table 3.1.

No significant difference in percent corneal weight loss occurred for corneas
incubated with serum stored for 0, 30, 90 or 180 days (P=0.074) (Table 3.2). No
significant difference in percent corneal weight loss occurred for corneas incubated in
fresh serum or serum stored at -20°C or -80°C (P=0.526) (Table 3.3).

HP Assay−Higher concentrations of HP were measured in incubation fluid from
positive control samples compared to fluid from negative control samples. Across
species, inclusion of feline and equine sera significantly reduced HP concentration (both
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P<0.001) compared to positive control samples. Inclusion of canine serum did not reduce
HP concentration compared to positive controls (P=0.229). HP concentrations for feline,
canine and equine corneas incubated in feline, canine and equine sera, including positive
and negative controls are summarized in Table 3.4. The amount of HP was significantly
lower for canine corneas incubated in feline serum compared to canine corneas incubated
in canine serum (P=0.007) but no other cornea/serum combinations were significantly
different (Table 3.4).

The HP concentration of incubation fluid from corneas incubated with serum stored
for 90 days was significantly higher than that of fresh serum (P<0.001), 30 day stored
serum (P<0.001) and 180 day stored serum (P<0.001) (Table 3.5). No significant
difference in the amount of HP was detected for corneas incubated with fresh serum or
serum stored at -20°C or at -80°C (p=0.132, Table 3.6).

Corneal weight loss was weakly correlated to HP concentration (Spearman’s
rho=0.12; P=0.096), where an increase in percent corneal weight loss corresponded to an
increase in HP concentration (Figure 1).
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Discussion

Sera from feline, canine, and equine species were all effective at reducing corneal
weight loss in this in vitro model. Feline and equine sera were effective at reducing HP
concentration. Neither storage time nor temperature resulted in a significant difference in
percent corneal weight loss or HP production. Interspecies use of serum did have a
significant effect on percent corneal weight loss, with feline serum being the most
protective regardless of the species of the corneal sample.

Proteinases are a group of enzymes that break down proteins; they can be
subdivided further into cysteine, aspartic, serine or metalloproteinases.10, 17 The MMPs
are a group of zinc dependent enzymes (which include collagenases) capable of
degrading collagen and other matrix proteins.1, 2,18, 19 In the cornea, MMPs are required
for general repair and remodeling of the stroma; they are balanced by endogenous
enzyme inhibitors. Dysregulation of this system can lead to uncontrolled collagen
breakdown.2, 19,20 This breakdown of corneal collagen, or keratomalacia, results from an
increase in collagenases from various sources, both endogenous (corneal epithelial cells,
leukocytes, tear film) and exogenous (bacterial or fungal organisms).1-4,7,8, 12,20

Many compounds have been investigated for their utility as corneal anticollagenolytic agents. Collagenase inhibitors can be divided into those that are specific
or nonspecific. Specific inhibitors block only one type of proteinase (serine for example)
while nonspecific inhibitors such as α macroglobulins can block all 4 types of
proteinases.16, 17 , 21 Topical agents, which have been effective collagenase inhibitors,
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include NAC, EDTA, tetracycline, tetanus antitoxin and autogenous serum.1, 2,

4,8,12

Both

EDTA and NAC exert their anti-collagenolytic effect by chelating zinc, and/or calcium,
which are required cofactors for the MMPs.2-4,22 Tetracycline, used topically or
systemically, chelates zinc and calcium, inhibits the breakdown of endogenous antitrypsin and may inhibit leukocyte migration.2-4,22 Serum contains α-2 macroglobulin, a
non-specific collagenase inhibitor, and alpha-1 antitrypsin.1-4,6-7,13-14,17 Human alpha-1
antitrypsin was found not to inhibit human corneal collagenase, although it did inhibit
rabbit corneal collagenase, whereas α-2 macroglobulin (in human and rabbit sera) was
inhibitory.6, 7,13 Human α-2 macroglobulin, a protein produced in the liver, accounts for 810 percent of serum proteins and inhibits both endogenous and exogenous collagenases
by forming tight complexes with the collagenase; kinetic studies have demonstrated that
α-2 macroglobulin is an important inhibitor of collagenases.2,13,16, 17,21 Wooley et al.23
found that greater than 90% of the anti-collagenase effect of serum was due to α-2
macroglobulin. Haffner et al.12 found no significant difference in the anti-collagenase
effects of equine serum, tetanus antitoxin and NAC in an in vitro corneal degradation
model and Ollivier et al.8 found that doxycycline, EDTA, NAC, ilomostat and equine
serum all inhibited latent and active forms of MMP. Serum has several potential
advantages over other anti-collagenases: it is well tolerated when used topically on the
eye and can be readily obtained from healthy donors. As such, serum is often used in both
human and veterinary practice as an anti-collagenase.

Despite its widespread use, few guidelines exist regarding the storage of serum for
topical use and of those that have been published, few provide data to support the
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recommendations regarding storage time or temperature.24-26 One report notes possible
storage protocols: store fresh serum at 4°C for no more than 16 hours or freeze serum at 20°C and store it for up to 3 months; serum can be stored frozen for 6 months but once in
use should be disposed of after a day.26 Liu et al.24 investigated the effects that
preparation methods have on epitheliotrophic factors present in human serum. Based on
their findings, they suggested that serum be allowed to clot at room temperature for 2
hours and subsequently be centrifuged for 15 minutes at 3,000 g. Once obtained the
serum should be diluted 1:4 with balanced saline solution and stored at -20°C for no
longer than 3 months, although they did not investigate effects of storage time or
temperature. Tsubota et al.25 investigated the effects of storage on several components
of serum for ocular use, comparing concentrations of epithelial growth factor, vitamin A
and TGF-β1 in fresh serum to that which had been stored for 1 month at 4°C or 1 and 3
months at -20°C. No differences in concentrations of the studied components were found
among the storage times, but there was no investigation of effect of storage on α-2
macroglobulin concentrations.

Published storage recommendations for veterinary ophthalmic use have varied. Serum
can reportedly be stored indefinitely if frozen, or stored at room temperature or
refrigerated and replaced every 8 days due to concerns regarding microbial
contamination.2,4 A previous study by Brooks et al.e reported that equine serum stored at
-18°C, 4°C and at 23°C for 7 days had no decrease in its ability to inactivate MMPs in
equine tears over a 7 day period, nor was there a difference in inhibitory activity between
the different temperatures. The results of the current study demonstrated that neither the
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storage time (up to 180 days) nor the storage temperatures evaluated (-20°C or -80°C)
had a significant effect on the percent corneal weight loss in an in vitro corneal ulcer
model. This is consistent with the results of Brooks et al.e and Tsubota et al.25 but our
study evaluated a longer storage time period and investigated only anti-collagenase
efficacy. Since our study did not evaluate serum stored at room temperature or 4°C we
cannot compare our results with regards to these temperature conditions. Further studies
are needed to evaluate the maximum time that serum could be stored at various
temperatures without loss of efficacy.

Quantification of HP, a breakdown product of collagen, has proven useful for
investigating collagen degradation.27 In the study by Haffner et al.12 corneal weight loss
and HP were highly correlated (r =0.80), where an increase in corneal weight loss
corresponded to increased HP concentration. This is in contrast to our results, where
percent corneal weight loss and the amount of HP were only weakly correlated
(Spearman’s rho =0.12), although an increase in percent corneal weight loss did
correspond to increased HP. Inclusion of feline and equine serum overall reduced the
amount of HP in incubation media, while inclusion of canine serum did not, indicating
that more collagen breakdown occurred in the presence of canine serum compared to
equine and feline sera. Storage temperature did not significantly affect the HP
concentration. The HP concentration from samples incubated in serum stored for 90 days
was significantly higher compared to serum stored for 0, 30 and 180 days. Clinically, this
result may not be relevant, as no reason for this discrepancy could be found.
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Additionally, corneas incubated in serum stored for 90 days did not have significantly
more weight loss compared to other time points.

As expected, the inclusion of serum in this in vitro model resulted in decreased
percent corneal weight loss compared to positive controls. Interestingly, feline serum
was the most protective across all the species of cornea on which it was tested. Knowing
that α-2 macroglobulin is the molecule responsible for the anti-collagenase effect and that
it comprises 8-10 percent of human serum proteins, it is tempting to speculate that feline
α-2 macroglobulin may be present in greater concentrations or has superior binding
capacity compared to canine or equine α-2 macroglobulin, but this has not been
investigated. Future research into characterizing α-2 macroglobulin of different species
and whether there are species differences in its binding capacity should be undertaken.
Predicted protein sequences for Isoforms X1 and X2 of canine α-2 macroglobulin, feline
α-2 macroglobulin and equine α-2 macroglobulin were identified on the National Center
for Biotechnology Information website.28 The protein sequence was also available for
human α-2 macroglobulin. A Basic Local Alignment Search Tool (BLAST) search and
comparison were performed: The predicted α-2 macroglobulin isoforms x1 and x2
(canine) have 99% conserved domains, Isoform x1 and x2 have 82% conserved domains
compared to the horse and 86% conserved domains compared to the cat.29 The feline
predicted α-2 macroglobulin has 86% conserved domains compared to the dog x1 and x2
and 81% conserved domains compared to the horse.29 The predicted α-2 macroglobulin
of the horse has 82% conserved domains to canine isoforms x1 and x2, and 81%
conserved domains to the cat.29 The human α-2 macroglobulin has 81% conserved to the
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horse, 80% compared to canine isoforms X1 and X2, and 80% compared to the feline.29
These similarities suggest that the α-2 macroglobulins of the species studied should
perform similarly, although this cannot be definitively stated. A recommendation of
preferentially using feline serum topically cannot be made without further study.
Additionally, as feline patients may be infected with contagious viruses, the use of feline
serum from untested cats on other feline patients cannot be recommended.

It is also possible that differences in the corneas themselves, rather than the inhibitory
effects of serum, are responsible for the interspecies differences in percent corneal weight
loss. Previous investigations into the corneas of domestic species have shown some
differences in corneal collagen type and thickness with respect to age, sex and species.3033

As this study evaluated percent corneal weight loss, absolute corneal weight and

composition were not important parameters, although we cannot say with certainty that
collagen type could not play a role.

This study demonstrated serum can be stored for up to 180 days at either -20° C or 80° C with no loss of anti-collagenase efficacy in this in vitro model. Feline serum may
be most efficacious but further research into differences in feline, canine and equine α-2
macroglobulins are needed.
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Figure 3.1 Scatter plot of hydroxyproline (HP) concentration versus percent corneal
weight loss. HP concentration was weakly correlated to percent corneal weight loss
(Spearman’s rho=0.12; P=0.096
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Table 3.1 Mean percent corneal weight loss for feline, canine or equine corneas incubated
with feline, canine or equine serum. Overall, corneas incubated in feline serum had the
least percent corneal weight loss compared to canine or equine serum (*, P<0.001). ).
Feline corneas incubated in feline serum had significantly less percent corneal weight
loss than feline corneas incubated in canine serum (†, P=0.002). Canine corneas
incubated in feline serum had significantly less percent corneal weight loss than canine
corneas incubated in canine serum (ǂ, P=0.008), Equine corneas incubated in feline serum
had significantly less percent corneal weight loss than equine corneas incubated in canine
serum (§, P<0.001) and equine corneas incubated in equine serum (||, P=0.019). Equine
corneas incubated in equine serum also had significantly less percent corneal weight loss
than equine corneas incubated in canine serum (¶, P=0.004).

Mean (SD) percent corneal weight loss
Cornea

Serum

Feline

Canine

Equine

Negative Control

6 (4)

6 (5)

4 (2)

Positive Control

77 (10)

93 (5)

72 (12)

Feline

52 (16)*,†

55 (17)*,ǂ

24 (15)*,§, ||

Canine

74 (10)†

74 (17)ǂ

62 (12)§

Equine

66 (10) ¶

63 (6)

39 (16) ||,¶
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Table 3.2 Mean (SD) percent corneal weight loss relative to serum storage time, across
all species cornea/sera combinations. Storage time did not significantly affect percent
corneal weight loss. (P=0.074)

Day

Percent Weight
Loss (SD)

0

63 (13)

30

48 (22)

90

58 (19)

180

60 (22)

Table 3.3 Mean (SD) percent corneal weight loss relative to storage temperature, across
all species cornea/sera combinations. Storage temperature did not significantly affect
percent corneal weight loss. (P=0.526)

Temperature

Percent
Weight Loss
(SD)

Fresh

63 (13)

-20

56 (23)

-80

55 (20)
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Table 3.4 Median HP concentration (µg/mL) of the incubation media using heterologous
sera. Across species, inclusion of feline* and equine† sera significantly reduced HP
concentrations (P <0.001) compared to positive control samples. Inclusion of canine
serum did not reduce HP concentration compared to positive controls (P=0.229). Canine
corneas incubated in feline serum had significantly less HP than canine corneas incubated
in canine serum (ǂ, P<0.05)
Cornea
Feline

Canine

Equine

Negative Control

0.0003 (0-0.003)

0 (0-0.009)

0.0014 (0-0.006)

Positive Control

0.04 (0.03-0.09)*,†

0.04 (0.02-0.11)*,†

0.08 (0.04-0.149)*,†

0.040 (0-0.086)*

0.025 (0-0.056)* ǂ

0.036 (0-0.138)*

Canine

0.032 (0.009-0.112)

0.042 (0.028-0.101) ǂ

0.055 (0.027-0.134)

Equine

0.039 (0.016-0.058)†

0.033 (0.008-0.060)†

0.038 (0.005-0.087)†

Serum Feline
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Table 3.5 Median (range) HP concentration with respect to storage time. Significantly
more HP was present in fluid from corneas incubated in serum stored for 90 days*
compared to fresh (P<0.001), 30 (P<0.001) or 180 (P<0.001) day serum.
Storage Time
(days)

HP
(µg/mL)

0

0.034 (0.005-0.086)

30

0.033 (0-0.079)

90

0.055 (0.022-0.138)*

180

0.032 (0.016-0.086)

Table 3.6 Median (range) HP concentration with respect to storage temperature. There
was no significant difference in HP concentrations with respect to storage temperature.
(P=0.132)
Storage Temperature

HP (μg/m)

Fresh

0.034 (0.005-0.086)

-20º C

0.040 (0-0.134)

-80º C

0.039 (0-0.138)
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4.2

Abstract

Objective−To compare the anti-collagenase efficacy of fresh feline, canine and
equine serum to plasma in an in vitro corneal degradation model. Samples−Normal
corneas from recently euthanized dogs, cats and horses; serum and plasma from healthy
dogs, cats, and horses. Procedures− Serum and plasma were pooled by species and used
fresh in the in-vitro model. Corneas were collected and stored at -80°C. Sections of
cornea were dried, weighed and incubated in saline with clostridial collagenase and
homologous fresh serum or plasma. Corneal degradation was assessed by percent corneal
weight loss and hydroxyproline (HP) concentration compared to positive and negative
controls. Results− Serum and plasma significantly reduced percent corneal weight loss
compared to positive controls in this model. No significant difference was found between
feline (P=0.579), canine (P=0.249) or equine (P=0.406) corneas incubated with serum or
plasma with regards to percent corneal weight loss. Canine serum and plasma
significantly reduced HP levels while inclusion of feline and equine serum or plasma did
not, compared to positive controls. HP levels were moderately correlated with percent
corneal weight loss for feline sample (P=0.002), weakly correlated for equine samples
(P=0.096) but were not correlated with percent corneal weight loss for canine samples
(P=0.842). Conclusions and Clinical Relevance− In this model, the anti-collagenase
efficacy of fresh feline, canine and equine serum was not different to that of plasma.
Plasma should be an acceptable substitute for topical serum in the clinical treatment of
keratomalacia.
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4.3

Introduction

The development of corneal ulceration is a frequent problem in domestic species. The
progression of corneal ulcers via degradation of corneal stroma is known to be mediated
by collagenases, enzymes that can come from infectious organisms, leukocytes or corneal
epithelial cells.1-3 Inhibition of these destructive enzymes can thus be crucial to
preventing further progression of corneal degradation.2

Topical serum has been utilized in human and veterinary medicine for various ocular
conditions. In human medicine, topical serum is utilized to treat dry eye, persistent
epithelial defects, neurotrophic keratopathy, superior limbic keratoconjunctivitis and
Mooren’s ulcers.4,5 Umbilical cord serum has also been investigated as a treatment for
acute ocular chemical burns.6 In veterinary medicine, topical serum has been widely
used as an anti-collagenase when treating corneal stromal ulcers in an attempt to slow or
arrest their progression.2,3,7 The anti-collagenase effect of topical serum is attributed to
the presence of α-2 macroglobulin, a serum protein which complexes with and inhibits
corneal collagenase.8,9

Plasma has also been investigated in human medicine for potential benefits when
used topically. Plasma has some possible benefits over serum, namely that plasma is
commercially available and therefore perhaps easier to obtain; plasma also contains
clotting proteins and platelets, which provide sustained release of growth factors.10,11
Hartwig et al.12 compared serum and fresh frozen plasma (FFP) in a human corneal
epithelial cell model to determine their relative effects on various aspects of corneal
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wound healing and found that serum was superior to FFP with regards to enhancing
epithelial cell growth, differentiation and migration. Numerous other studies have
evaluated FFP, platelet rich plasma (PRP) and platelet releasate (a product where the
growth factors in platelets are released by thrombin stimulation and the remaining platelet
membranes are removed by centrifugation) for treatment of ocular surface defects, ocular
burns, non-healing corneal ulcers, corneal perforations and dry eye and found clinical
improvement with their use.10-11,13-19

Despite previous research into the effects of plasma and its constituents on corneal
conditions in humans, there has been little investigation into the anti-collagenase efficacy
of plasma in veterinary medicine. Two previous studies20, 21 have evaluated canine
plasma in vitro in comparison to serum with regards to their anti-collagenase efficacy but
to the authors’ knowledge, no studies have evaluated the anti-collagenase efficacy of
feline or equine plasma compared to serum. The purpose of this study was to compare
the anti-collagenase efficacy of fresh feline, canine and equine serum to that of plasma in
an in vitro corneal degradation model.

4.4

Materials and Methods

Corneal Samples−Corneas were collected from recently euthanized dogs, cats and
horses from the Purdue University Veterinary Teaching Hospital or a local animal
shelter. Animals were euthanized for reasons unrelated to this study and had no evidence
of corneal disease as determined by examination with a direct light source. The corneas
were removed and sectioned into 4 pieces (feline and canine) or 6 pieces (equine) of
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roughly equal size. Each piece of cornea was stored individually, labeled by species and
kept at -80°C until use. Corneal sections were stored for time periods of 1-18 months
before use. Storage times for corneal samples were evenly distributed among control and
test groups.

Serum and Plasma Samples−Whole blood was obtained from healthy canine (n=4),
feline (n=4) and equine (n=4) donors. The dogs and cats were employee owned animals,
whereas the horses were Purdue University owned teaching animals. Cats were
anesthetized for blood collection, whereas dogs and horses were manually restrained. To
obtain serum, blood was collected into serum separator tubesa, allowed to clot, and
centrifuged to separate the serum. The serum was then removed and pooled by species.
To obtain plasma, the blood was collected into lithium heparin tubesb and centrifuged to
separate the plasma. To avoid confounding the results, EDTA was not used as an
anticoagulant as EDTA has anti-collagenase properties. The plasma was then removed
and pooled by species. The pooled serum and plasma were then used within 24 hours. All
procedures were approved by the Purdue University Animal Care and Use Committee.
Employees signed written consent forms authorizing the use of their pets for blood
collection. Sterile technique was used throughout the experiment but no bacterial cultures
were performed on the pooled serum or plasma.

In Vitro Corneal Degradation Model− Individual corneal samples were placed in
plastic weigh boats and dried in a 40° C oven for 3 hours. After drying, the pre-treatment
corneal weight was recorded. Incubation fluid was prepared by adding 800 U/mL of
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collagenase derived from Clostridium histolyticumc to 5 mM calcium chloride in 0.9%
sodium chloride. Five mL of the incubation fluid was added to a 10 mL tube containing
the corneal sample. Then 500 µL of serum or 500 µL of plasma from the appropriate
species was added to the incubation fluid so that sections of cornea were incubated with
either homologous serum or homologous plasma. Negative controls consisted of 5 mL of
5 mM calcium chloride in 0.9% sodium chloride only. Positive controls consisted of 5
mM calcium chloride in 0.9% sodium chloride with 800 U/mL of clostridial collagenase
but with neither serum nor plasma. For each species, 15 corneal samples were incubated
individually with serum and 15 corneal samples were incubated individually with plasma.
Positive and negative control samples for each species were run in triplicate. Tubes were
incubated with agitation at 40°C for 4 hours. After incubation, 1.8 mL of incubation fluid
was collected from each tube and stored at -80°C for HP analysis at a later date. The
cornea was then collected by pouring the remaining solution through Whatman filter
paper.d The post treatment corneas were then dried at 40°C for 3 hours, weighed and the
post treatment percent corneal weight loss recorded.

HP Assay−As a second method of evaluating corneal collagen degradation, HP
concentration in the incubation media was evaluated using a commercial HP
spectrophotometric assay kite. The analyses were performed according to kit instructions
with two modifications: samples were diluted 1:2 with ultrapure water prior to analysis to
ensure HP concentrations measured would fit on the standard curve and samples were
centrifuged for 10 minutes at 10,000 rpm. A new standard curve was calculated for each
plate per kit instructions.
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Statistical Analysis- Kruskal-Wallis tests were used to compare percent corneal
weight loss and HP levels among serum, plasma and positive controls. Dunn’s tests were
performed for pairwise comparisons following a significant Kruskal-Wallis test (i.e.,
P<0.05). Correlation between percent corneal weight loss and HP concentration was
assessed by Spearman correlation coefficient. Only serum and plasma samples were
analyzed for correlation, positive and negative control sample results were not included
in this calculation.

4.5

Results

In Vitro Corneal Degradation Model−This model was effective at producing corneal
weight loss by collagen degradation. The mean (SD) percent corneal weight loss for
feline, canine and equine positive controls were 85% (3), 100% (4) and 76% (13)
respectively while the mean (SD) percent corneal weight loss for feline, canine and
equine negative controls were 4% (2), 4% (4) and 1% (2) respectively. The mean (SD)
percent corneal weight loss for feline, canine and equine corneas incubated in serum were
62% (7), 74% (15) and 38% (12) respectively. The mean (SD) percent corneal weight
loss for feline, canine and equine corneas incubated in plasma were 60% (10), 60% (27)
and 41% (14), respectively.

Serum and plasma were both effective at reducing percent corneal weight loss
compared to positive controls in this study. Inclusion of feline, canine or equine serum,
on average, reduced corneal weight loss by 23% (P=0.012), 26% (P=0.018) and 38%
(P=0.005) compared to respective positive control samples. Inclusion of feline, canine or
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equine plasma, on average, reduced corneal weight loss by 25% (P=0.004), 40%
(P=0.002) and 35% (P=0.019) respectively compared to respective positive control
samples. There was no significant difference in corneal weight loss between corneas
incubated with serum or plasma: feline (P=0.579), canine (P=0.249) or equine (P=0.406)
(Figure 4.1).

HP Assay− Higher concentrations of HP were measured in incubation fluid from
positive control samples compared to fluid from negative control samples. The mean
(SD) HP level (µg/mL) for feline, canine and equine positive controls were 0.04 (0.004),
0.04 (0.04) and 0.04 (0.02), respectively while the mean (SD) HP level (µg/mL) for
feline, canine and equine negative controls were 0.001 (0.001), 0.004 (0.007), and 0.007
(0.01), respectively. The mean (SD) HP level (µg/mL) for feline, canine and equine
corneas incubated in serum were 0.04 (0.01), 0.01 (0.01) and 0.06 (0.03), respectively.
The mean (SD) HP level (µg/mL) for feline, canine and equine corneas incubated in
plasma were 0.04 (0.01), 0.01 (0.01) and 0.06 (0.03), respectively.

The inclusion of canine serum (P=0.028) or canine plasma (P=0.009) significantly
reduced HP concentration compared to positive controls (Figure 4.2). There was no
significant difference in HP concentration between corneas incubated with canine serum
or canine plasma (P=0.497). There was no significant difference in HP concentrations
between positive control samples and samples incubated with feline serum or plasma
(P=0.480) or equine serum or plasma (P=0.846). (Figure 4.2).
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Correlation- Spearman’s correlation coefficients were 0.54 (P=0.002), 0.04
(P=0.842) and 0.31(P=0.096) for feline, canine and equine samples, respectively (Figure
4.3 A-C).

4.6

Discussion

In this study plasma and serum were equally effective in all species tested at reducing
corneal weight loss in vitro. This finding suggests that either plasma or serum could be
used topically on an eye with keratomalacia with equal benefit. Serum has been used
extensively to treat many different ocular diseases in both humans and domestic species.25,7

The beneficial effects of topical serum can be attributed to constituent growth factors,

vitamins, neuropeptides and anti-collagenases.4 A number of these, including EGF,
TGF-β, fibronectin and substance P, promote migration and adhesion of corneal epithelial
cells as well as corneal stromal and epithelial repair.4 Vitamin A can help to stop
corneal squamous metaplasia, while α-2 macroglobulin exhibits anti-collagenase effects.
Fibronectin is a supportive factor in cellular migration.4 Serum also contains
immunoglobulins, which can be bacteriostatic, or bactericidal.4 Many of these factors
(EGF, TGF-β1, vitamin A, fibronectin) are present in higher concentrations in serum than
in tears.4 Potential risks of topical serum usage include blood borne disease transmission,
the deposition of immunoglobulins in the cornea and contamination of the serum with
bacteria.4-5 Most of the benefits seen in human cases where topical serum has been used
have been related to improvement in clinical signs, healing of persistent ulcers and
reduced recurrence of ulcers rather than anti-collagenase activity.4-5 In veterinary
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medicine, serum has primarily been used for its anti-collagenase effects rather than for
epithelial healing.2-3,7

Given its similar composition to serum, plasma has also been studied for ophthalmic
usage, although it too is mostly evaluated for its ability to affect corneal epithelial growth
and not for its anti-collagenase effect. When activated, platelets in plasma release growth
factors and other cytokines, which can contribute to the corneal healing process. Serum
has been compared to FFP, and to platelet releasate with regards to their respective
corneal epitheliotrophic capacities.12,17 Hartwig et al.12 compared the concentrations of
EGF, PDGF, TGF-β, fibronectin and vitamin A in serum and FFP; they also assessed the
effects of either blood product on corneal epithelial cells in vitro. In that study, serum had
significantly higher concentrations of all the factors except for fibronectin, which was
present in similar amounts to that in FFP; serum was significantly better at stimulating
cell growth, migration and differentiation compared to FFP. In 2006, Liu et al.17
investigated the concentrations of EGF, PDGF, TGF-β, fibronectin, vitamin A and
vitamin E in serum, FFP and platelet releasate. In the Liu study serum had significantly
higher levels of fibronectin and vitamins A and E, whereas platelet releasate had
significantly higher levels of EGF, PDGF and TGF-β than serum, which had more of the
same factors than FFP.17 In the same study, in vitro corneal cell proliferation was best
supported by platelet releasate, followed by serum and then FFP but cell differentiation
and migration were best supported by serum.17 These results are similar to that of an
earlier in vitro study, which compared serum with platelet releasate and found that
platelet releasate resulted in significantly better cell growth while cell differentiation and
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migration were slightly improved with serum.16 These findings are consistent with what
we know about the various growth factors regarding corneal epithelium, for example that
PDGF stimulations cell proliferation while fibronectin stimulates cell migration.16

Platelet rich plasma specifically has been utilized topically to treat acute corneal
chemical burns, dry eye, non-healing corneal ulcers and used in conjunction with
autologous fibrin membranes to treat corneal perforations.10-11,13,15 The PRP can be
formulated for eyes in 2 ways - as a topical drop or as a clot, both of which have higher
concentrations of growth factors than serum.11 In one report, the PRP drop had a platelet
concentration of 800,000/µL whereas the clot had 4,000,000/µL.11 The normal circulating
concentration of platelets in humans is 150,000 to 450,000/µL.11 Alio et al.13 found that
topical PRP drops significantly improved the symptoms and clinical signs of human
patients with dry eye. In another study, Alio et al.11 also found that PRP, when used as a
topical drop or with surgical placement of a PRP clot under an amniotic membrane (for
eyes with impending or current perforations), improved healing of corneal ulcers that had
not responded to previous conventional treatment. A recent report details the use of a
combination of an autologous PRP clot and an autologous fibrin membrane to surgically
treat 11 patients with corneal perforations, with no reported complications and no
evidence of relapse or perforation after 3 months, with 7 of 11 eyes eventually receiving
corneal transplants.15

Plasma and its various iterations are supportive of corneal epithelial healing, but there
is little investigation into the anti-collagenase efficacy of plasma. Alio et al.11 used

72
reduction of depth of the ulcer as a primary outcome measure but did not specifically
investigate anti-collagenase activity. One report noted that the concentration of α-2
macroglobulin in human API-PRP was increased 5-10 fold compared to the α-2
macroglobulin concentration of blood.f This suggests that the anti-collagenase activity of
PRP could be superior to that of serum, although studies to quantify the amount of α-2
macroglobulin in serum of non-human species would be needed before direct
comparisons could be made. One veterinary study evaluated the anti-collagenase activity
of fresh canine serum and plasma, as well as frozen canine plasma, with a commercial
gelatinase and collagenase kit.20

In that study serum was superior to either plasma

product with regards to decreasing protease activity although all three substances were
effective.20 Another veterinary study compared canine serum, canine FFP, canine freezethaw cycled plasma and Solcoseryl (an commercial ultrafiltrate of calf blood which is
free of protein) using a gelatinase kit; results showed that Solcoseryl only inhibited
matrix metalloproteinase-9, while serum, FFP and canine freeze thawed plasma had
comparable levels of inhibition for both matrix metalloproteinase-2 and matrix
metalloproteinase-9.21 These results are similar to the results obtained in the present
study, where serum and plasma did not differ in their anti-collagenase efficacy.

With regards to HP levels in the incubation media, higher levels of HP were detected
in positive control samples compared to negative control samples. Inclusion of canine
serum or plasma resulted in significantly lower levels of HP while the inclusion of feline
and equine serum and plasma did not significantly reduce HP levels. Overall, when

73
comparing the HP levels of incubation fluid for feline, canine and equine corneas, there
was no significant difference in the HP levels with serum compared to plasma.

In the current study, HP levels were moderately correlated with percent corneal
weight loss for feline samples, moderately correlated with equine samples, but were not
correlated with percent corneal weight loss for canine samples. One previous study1
showed a strong positive correlation between equine corneal weight loss due to collagen
degradation and HP levels of the incubation fluid, while a previous study in our
laboratory found only weak correlation between percent corneal weight loss and HP
levels.22 The current results, along with our previous results, show that HP levels may
vary widely, making their interpretation more difficult.

The results of the current study demonstrate that the anti-collagenase efficacy of
plasma and serum do not differ in this in vitro model. This finding suggests that either of
the two compounds could be used for treating keratomalacia. Additional studies are
needed to determine if the anti-collagenase efficacy of plasma is comparable to serum in
vivo and also to determine if PRP or plasma releasate could be of value with regards to
anti-collagenase activity.
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Figure 4.1 Mean (SD) percent corneal weight loss of feline, canine and equine corneal
samples incubated in serum or plasma. There was no significant difference between
feline (P=0.579), canine (P=0.249) or equine (P=0.406) corneas incubated with serum
compared to plasma.
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Figure 4.2 Mean (SD) HP levels of feline, canine and equine corneal samples incubated
in serum or plasma. The inclusion of canine serum (P=0.028) or canine plasma (P=0.009)
significantly reduced HP concentration compared to positive controls. There was no
significant difference in HP concentration between corneas incubated with canine serum
or canine plasma (P=0.497). No significant difference in HP concentrations between
positive control samples and samples incubated with feline serum or plasma (P=0.480) or
equine serum or plasma (P=0.846) was found.
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Figure 4.3 (A-C) - Scatter plots of hydroxyproline (HP) concentration versus percent
corneal weight loss. A: Feline, moderate correlation; Spearman’s correlation coefficient
(ρ) = 0.54 (P=0.002); B: Canine, no correlation; Spearman’s ρ = 0.04 (P=0.842); C:
Equine, moderate correlation; Spearman’s ρ = 0.31 (P=0.096)
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Footnotes:
a. BD Vacutainer serum separator blood collection tube, Becton, Dickinson and
Company, Franklin Lakes, NJ.
b. BD Vacutainer lithium heparin blood collection tube, Becton, Dickinson and
Company, Franklin Lakes, NJ.
c. Collagenase from Clostridium histolyticum, Type XI, Sigma Aldrich, St Louis, Mo.
d.

Whatman filter paper, Sigma Aldrich, St Louis, Mo.

e. Hydroxyproline assay kit, Sigma Aldrich, St Louis, Mo.
f. Browning SR, Carballo C, Golish SR et al. Can cartilage degradation be prevented by
platelet rich plasma (PRP) preparations on bovine cartilage explants? (abstr) Am J Phys
Med Rehabil. 2012:s193.
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS

5.1

Conclusion

Several investigations into the anti-collagenase efficacy of blood products were
undertaken over a 3-year period. The initial study evaluated the effects of storage time
and storage temperature on the in vitro anti-collagenase efficacy of serum in a corneal
degradation model. Secondary to this primary goal was an investigation into interspecies
use of serum as an anti-collagenase. A final study aimed to compare the in vitro anticollagenase efficacy of fresh serum to that of plasma for feline, canine and equine
species. This study also examined ways to quantify corneal degradation in vitro, by
measurement of percent corneal weight loss and hydroxyproline concentration in
incubation media from the various experimental conditions.

Melting corneal ulcers are a frequently encountered condition in clinical
ophthalmology. Regardless of the inciting cause of the ulceration, the presence of
degradative enzymes from infectious agents, invading PMNL and from endogenous
sources (epithelial and stromal cells) contribute to progression of stromal loss. The
ability to slow or stop the destruction of the stroma can be key to saving vision or even
salvage of the globe. The use of topical or systemic inhibitors of collagenases has been
recommended for decades, in both human and veterinary medicine, but these

81
recommendations are often lacking in data to support their storage and use. As expected,
addition of serum to the incubation media was protective in this in vitro model; resulting
in less percent corneal weight loss compared to corneas incubated only with clostridial
collagenase. This study has demonstrated that feline, canine and equine serum can be
stored for up to 180 days at either -20° C or -80° C with no loss of anti-collagenase
efficacy in this in vitro model. Differences in the interspecies anti-collagenase efficacy
were noted. Feline serum was the most efficacious in this particular study but further
research into differences in feline, canine and equine α-2 macroglobulins is needed; it is
possible that amounts of α-2 macroglobulin differ between species or that they behave
differently with respect to collagenase binding .

The second study demonstrated that the addition of serum or plasma was effective at
decreasing the amount of corneal weight loss, compared to positive controls incubated
with clostridial collagenase only. There was no significant difference in the amount of
corneal weight loss that occurred for feline, canine and equine corneas incubated with
serum compared to plasma. The results found here are roughly in agreement with
previous studies, which found that canine plasma possessed similar anti-collagenase
efficacy to that of canine serum.1,2

With regards to the assays of HP levels, slightly discordant results were found
between the two studies performed as part of this thesis. In this first research
investigation the level of HP was found to be only weakly correlated to percent corneal
weight loss, even though an increase in percent corneal weight loss corresponded to
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higher levels of HP. In the second study performed, the inclusion of canine serum or
plasma resulted in significantly lower levels of HP while the inclusion of feline and
equine serum and plasma did not significantly reduce HP levels. Overall, when
comparing the HP levels of incubation fluid for feline, canine and equine corneas, there
was no significant difference in the HP levels with respect to the addition of serum
compared to plasma. In contrast to the first study, HP levels were moderately correlated
with percent corneal weight loss for feline and equine samples but were not correlated
with percent corneal weight loss for canine samples. A previous study showed
correlation between corneal weight loss due to collagen degradation and HP levels of the
incubation fluid.3 The current results, along with our previous results, show that HP
levels may vary widely, making their interpretation more difficult.

Current recommendations are that serum for topical use can be stored for at least 6
months at temperatures of -20°C or -80°C.

5.2

Future Directions

Future investigations in this field should include an assessment of the sterility of
serum or plasma stored at varying temperatures for varying lengths of time, as this was
not investigated here. As always, the results of experiments performed in a lab cannot
necessarily be translated to clinical practice. An in vivo investigation into interspecies
use of serum, where heterologous serum would be used topically for veterinary patients
with keratomalacia, could help to determine if serum from a particular species is truly
superior. An in vivo investigation into the topical utility of serum compared to that of
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plasma should be undertaken, prior to the recommendation of plasma as a topical anticollagenase for clinical patients. Also, investigations into quantifying α-2 macroglobulin
levels of serum and plasma products could be performed.
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